Age-related macular degeneration.
Saved in:
| Title: | Age-related macular degeneration. |
|---|---|
| Authors: | Lim LS (AUTHOR), Mitchell P (AUTHOR), Seddon JM (AUTHOR), Holz FG (AUTHOR), Wong TY (AUTHOR), Lim, Laurence S (AUTHOR), Mitchell, Paul (AUTHOR), Seddon, Johanna M (AUTHOR), Holz, Frank G (AUTHOR), Wong, Tien Y (AUTHOR) |
| Source: | Lancet. 5/5/2012, Vol. 379 Issue 9827, p1728-1738. 11p. |
| Subjects: | Retinal degeneration treatment, Retinal degeneration, Injections, Intraocular drug administration, Research funding, Angiography |
| Abstract: | Age-related macular degeneration is a major cause of blindness worldwide. With ageing populations in many countries, more than 20% might have the disorder. Advanced age-related macular degeneration, including neovascular age-related macular degeneration (wet) and geographic atrophy (late dry), is associated with substantial, progressive visual impairment. Major risk factors include cigarette smoking, nutritional factors, cardiovascular diseases, and genetic markers, including genes regulating complement, lipid, angiogenic, and extracellular matrix pathways. Some studies have suggested a declining prevalence of age-related macular degeneration, perhaps due to reduced exposure to modifiable risk factors. Accurate diagnosis combines clinical examination and investigations, including retinal photography, angiography, and optical coherence tomography. Dietary anti-oxidant supplementation slows progression of the disease. Treatment for neovascular age-related macular degeneration incorporates intraocular injections of anti-VEGF agents, occasionally combined with other modalities. Evidence suggests that two commonly used anti-VEGF therapies, ranibizumab and bevacizumab, have similar efficacy, but possible differences in systemic safety are difficult to assess. Future treatments include inhibition of other angiogenic factors, and regenerative and topical therapies. [ABSTRACT FROM AUTHOR] |
| Copyright of Lancet is the property of Lancet and its content may not be copied or emailed to multiple sites without the copyright holder's express written permission. Additionally, content may not be used with any artificial intelligence tools or machine learning technologies. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.) | |
| Database: | Psychology and Behavioral Sciences Collection |
| FullText | Text: Availability: 0 |
|---|---|
| Header | DbId: pbh DbLabel: Psychology and Behavioral Sciences Collection An: 108186479 AccessLevel: 6 PubType: Academic Journal PubTypeId: academicJournal PreciseRelevancyScore: 0 |
| IllustrationInfo | |
| Items | – Name: Title Label: Title Group: Ti Data: Age-related macular degeneration. – Name: Author Label: Authors Group: Au Data: <searchLink fieldCode="AR" term="%22Lim+LS%22">Lim LS</searchLink> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Mitchell+P%22">Mitchell P</searchLink> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Seddon+JM%22">Seddon JM</searchLink> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Holz+FG%22">Holz FG</searchLink> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Wong+TY%22">Wong TY</searchLink> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Lim%2C+Laurence+S%22">Lim, Laurence S</searchLink> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Mitchell%2C+Paul%22">Mitchell, Paul</searchLink> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Seddon%2C+Johanna+M%22">Seddon, Johanna M</searchLink> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Holz%2C+Frank+G%22">Holz, Frank G</searchLink> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Wong%2C+Tien+Y%22">Wong, Tien Y</searchLink> (AUTHOR) – Name: TitleSource Label: Source Group: Src Data: <searchLink fieldCode="JN" term="%22Lancet%22">Lancet</searchLink>. 5/5/2012, Vol. 379 Issue 9827, p1728-1738. 11p. – Name: Subject Label: Subjects Group: Su Data: <searchLink fieldCode="DE" term="%22Retinal+degeneration+treatment%22">Retinal degeneration treatment</searchLink><br /><searchLink fieldCode="DE" term="%22Retinal+degeneration%22">Retinal degeneration</searchLink><br /><searchLink fieldCode="DE" term="%22Injections%22">Injections</searchLink><br /><searchLink fieldCode="DE" term="%22Intraocular+drug+administration%22">Intraocular drug administration</searchLink><br /><searchLink fieldCode="DE" term="%22Research+funding%22">Research funding</searchLink><br /><searchLink fieldCode="DE" term="%22Angiography%22">Angiography</searchLink> – Name: Abstract Label: Abstract Group: Ab Data: Age-related macular degeneration is a major cause of blindness worldwide. With ageing populations in many countries, more than 20% might have the disorder. Advanced age-related macular degeneration, including neovascular age-related macular degeneration (wet) and geographic atrophy (late dry), is associated with substantial, progressive visual impairment. Major risk factors include cigarette smoking, nutritional factors, cardiovascular diseases, and genetic markers, including genes regulating complement, lipid, angiogenic, and extracellular matrix pathways. Some studies have suggested a declining prevalence of age-related macular degeneration, perhaps due to reduced exposure to modifiable risk factors. Accurate diagnosis combines clinical examination and investigations, including retinal photography, angiography, and optical coherence tomography. Dietary anti-oxidant supplementation slows progression of the disease. Treatment for neovascular age-related macular degeneration incorporates intraocular injections of anti-VEGF agents, occasionally combined with other modalities. Evidence suggests that two commonly used anti-VEGF therapies, ranibizumab and bevacizumab, have similar efficacy, but possible differences in systemic safety are difficult to assess. Future treatments include inhibition of other angiogenic factors, and regenerative and topical therapies. [ABSTRACT FROM AUTHOR] – Name: AbstractSuppliedCopyright Label: Group: Ab Data: <i>Copyright of Lancet is the property of Lancet and its content may not be copied or emailed to multiple sites without the copyright holder's express written permission. Additionally, content may not be used with any artificial intelligence tools or machine learning technologies. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract.</i> (Copyright applies to all Abstracts.) |
| PLink | https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&db=pbh&AN=108186479 |
| RecordInfo | BibRecord: BibEntity: Identifiers: – Type: doi Value: 10.1016/S0140-6736(12)60282-7 Languages: – Code: eng Text: English PhysicalDescription: Pagination: PageCount: 11 StartPage: 1728 Subjects: – SubjectFull: Retinal degeneration treatment Type: general – SubjectFull: Retinal degeneration Type: general – SubjectFull: Injections Type: general – SubjectFull: Intraocular drug administration Type: general – SubjectFull: Research funding Type: general – SubjectFull: Angiography Type: general Titles: – TitleFull: Age-related macular degeneration. Type: main BibRelationships: HasContributorRelationships: – PersonEntity: Name: NameFull: Lim LS – PersonEntity: Name: NameFull: Mitchell P – PersonEntity: Name: NameFull: Seddon JM – PersonEntity: Name: NameFull: Holz FG – PersonEntity: Name: NameFull: Wong TY – PersonEntity: Name: NameFull: Lim, Laurence S – PersonEntity: Name: NameFull: Mitchell, Paul – PersonEntity: Name: NameFull: Seddon, Johanna M – PersonEntity: Name: NameFull: Holz, Frank G – PersonEntity: Name: NameFull: Wong, Tien Y IsPartOfRelationships: – BibEntity: Dates: – D: 05 M: 05 Text: 5/5/2012 Type: published Y: 2012 Identifiers: – Type: issn-print Value: 01406736 Numbering: – Type: volume Value: 379 – Type: issue Value: 9827 Titles: – TitleFull: Lancet Type: main |
| ResultId | 1 |
